{"schema_version":"1","generated_at":"2026-11-20T13:38:01.765Z","data_as_of":null,"url":"https://www.findmykol.com/kol/ivor-percent","json_url":"https://www.findmykol.com/kol/ivor-percent/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"ivor-percent","name":"Ivor Percent","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Florida Cancer Specialists & Research Institute","institution_url":"https://www.findmykol.com/institution/florida-cancer-specialists-research-institute","city":"Port Charlotte","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Ivor Percent is an Oncology physician affiliated with Florida Cancer Specialists & Research Institute. OpenAlex indexes 53 publications with 2,724 citations (h-index 20).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":53,"cited_by_count":2724,"h_index":20,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":83,"program_years":{"first":2021,"last":null},"rows_total":254,"shown":3,"withheld":251,"rows":[{"payer":"Genentech","program_year":2025,"amount_usd":40577.5,"payment_count":9},{"payer":"Bristol Myers Squibb","program_year":2025,"amount_usd":33530,"payment_count":1},{"payer":"Genmab","program_year":2025,"amount_usd":30656.76,"payment_count":20}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":46,"classes_total":15,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":12.4,"drugs":[{"name":"Pembrolizumab","share_pct":58.3},{"name":"Nivolumab","share_pct":41.7}],"max_beneficiaries":25},{"class":"Leukocyte Growth Factor","setting":"administered","share_pct":11.4,"drugs":[{"name":"Filgrastim","share_pct":87.2},{"name":"Eflapegrastim-xnst","share_pct":12.8}],"max_beneficiaries":14}]},{"area":"Blood & clotting","share_pct":30.1,"classes_total":5,"classes":[{"class":"Parenteral Iron Replacement","setting":"administered","share_pct":12.9,"drugs":[{"name":"Iron sucrose","share_pct":100}],"max_beneficiaries":72},{"class":"Iron, parenteral preparations","setting":"administered","share_pct":10.3,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":21}]},{"area":"Metabolism & gastrointestinal","share_pct":8.2,"classes_total":4,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":6.7,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":44},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":1.3,"drugs":[{"name":"Palonosetron hcl","share_pct":62.7},{"name":"Ondansetron hydrochloride","share_pct":33.6},{"name":"Ondansetron Odt","share_pct":2.3},{"name":"Ondansetron Hcl","share_pct":1.4}],"max_beneficiaries":60}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","year":2026,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-026-04327-4","status":"verified"},{"title":"Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.2_suppl.653","status":"verified"},{"title":"Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-02995","status":"verified"},{"title":"A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting","year":2026,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyag279","status":"verified"},{"title":"Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4213","status":"verified"}],"source":"works"},"similar":[{"name":"Bradley Monk","slug":"bradley-monk","institution":"Florida Cancer Specialists & Research Institute","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/bradley-monk","json_url":"https://www.findmykol.com/kol/bradley-monk/profile.json"},{"name":"Bradford Perez","slug":"bradford-perez","institution":"Florida Cancer Specialists & Research Institute","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/bradford-perez","json_url":"https://www.findmykol.com/kol/bradford-perez/profile.json"},{"name":"Cesar Perez Batista","slug":"cesar-perez-batista","institution":"Florida Cancer Specialists & Research Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/cesar-perez-batista","json_url":"https://www.findmykol.com/kol/cesar-perez-batista/profile.json"},{"name":"Manish Patel","slug":"manish-patel","institution":"Florida Cancer Specialists & Research Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/manish-patel","json_url":"https://www.findmykol.com/kol/manish-patel/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":251,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}